Discovery of a small molecule ligand of FRS2 that inhibits invasion and tumor growth.
Karthiga Santhana KumarCyrill BrunnerMatthias SchusterLevi Luca KoppAlexandre GriesShen YanSimon JurtKerstin MoehleDominique BrunsMichael GrotzerOliver ZerbeGisbert SchneiderMartin BaumgartnerPublished in: Cellular oncology (Dordrecht) (2022)
Our results illustrate a phenotype-guided drug discovery strategy that identified a novel mechanism to repress FGFR-driven invasiveness and growth in human cancers. The here identified bioactive leads targeting FGF signaling and cell dissemination provide a novel structural basis for further development as a tumor agnostic strategy to repress FGFR- and FRS2-driven tumors.